Compugen Ltd. announced a virtual event on October 5, 2026, featuring Dr. Oladapo Yeku to discuss COM701, a novel anti-PVRIG antibody in development for relapsed platinum-sensitive ovarian cancer. The event will preview the MAIA-ovarian trial design and share updates on Compugen's AI-powered drug discovery platform, Unigen™. Interim progression-free survival data from the trial is expected by Q1 2027, marking a significant step in ovarian cancer treatment research. This highlights Compugen's ongoing innovation in cancer immunotherapy using AI/ML technologies.
Compugen's upcoming virtual event on COM701 in ovarian cancer research provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Sep 22, 2026 18:11 WIB: out of 95 priced US health-sector stocks, 50 rose and 38 fell. Notable movers include FLNA at USD 0.73 with 98% sell orders, DNA at USD 7.90 with 88% buy orders, and REGN at USD 790.72 with nearly balanced buy/sell activity.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
